Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1603
+0.00961 (6.38%)
At close: Aug 7, 2026
Integrated BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 48.25 | 54.35 | 50.32 | 50.67 | 56.25 | 63.56 | |
Revenue Growth | -8.83% | 8.02% | -0.70% | -9.91% | -11.51% | 20.45% |
Cost of Revenue | 46.01 | 48.79 | 46.43 | 46.61 | 49.69 | 54.08 |
Gross Profit | 2.24 | 5.56 | 3.88 | 4.06 | 6.55 | 9.48 |
Selling, General & Admin | 3.49 | 3.54 | 3.63 | 3.94 | 3.81 | 3.7 |
Operating Expenses | 3.49 | 3.54 | 3.63 | 3.94 | 3.81 | 3.7 |
Operating Income | -1.25 | 2.02 | 0.25 | 0.12 | 2.75 | 5.78 |
Interest Expense | -0.05 | -0.05 | -0.05 | -0.01 | -0.13 | -0.26 |
Interest & Investment Income | 0.17 | 0.09 | 0.07 | - | - | - |
Other Non Operating Income (Expenses) | 0.01 | 0 | -0 | -0.01 | 0.01 | 0.06 |
EBT Excluding Unusual Items | -1.12 | 2.06 | 0.27 | 0.1 | 2.63 | 5.59 |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.06 | 0 |
Gain (Loss) on Sale of Assets | -0.03 | - | - | - | 0.02 | - |
Asset Writedown | 0.03 | - | - | - | - | - |
Other Unusual Items | - | - | - | - | - | 1.66 |
Pretax Income | -1.12 | 2.06 | 0.27 | 0.1 | 2.6 | 7.25 |
Income Tax Expense | 0.54 | 1.25 | 0.16 | 0.13 | -1.24 | -0.77 |
Net Income | -1.65 | 0.81 | 0.11 | -0.03 | 3.84 | 8.01 |
Net Income to Common | -1.65 | 0.81 | 0.11 | -0.03 | 3.84 | 8.01 |
Net Income Growth | - | 621.43% | - | - | -52.10% | 95.06% |
Shares Outstanding (Basic) | 31 | 30 | 30 | 30 | 30 | 30 |
Shares Outstanding (Diluted) | 31 | 31 | 31 | 30 | 32 | 32 |
Shares Change | -1.92% | 0.95% | 3.08% | -7.34% | 0.65% | 3.07% |
EPS (Basic) | -0.05 | 0.03 | 0.00 | -0.00 | 0.13 | 0.27 |
EPS (Diluted) | -0.05 | 0.03 | 0.00 | -0.00 | 0.12 | 0.25 |
EPS Growth | - | 635.32% | - | - | -52.00% | 92.31% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | 2.84 | 1.87 | 0.39 | 1.12 | 3.61 | 2.76 |
Free Cash Flow Per Share | 0.09 | 0.06 | 0.01 | 0.04 | 0.11 | 0.09 |
Gross Margin | 4.64% | 10.23% | 7.72% | 8.01% | 11.65% | 14.92% |
Operating Margin | -2.58% | 3.72% | 0.50% | 0.24% | 4.88% | 9.10% |
Profit Margin | -3.43% | 1.49% | 0.22% | -0.07% | 6.82% | 12.61% |
Free Cash Flow Margin | 5.88% | 3.45% | 0.78% | 2.20% | 6.41% | 4.33% |
EBITDA | -0.95 | 2.34 | 0.56 | 0.47 | 3.08 | 6.12 |
EBITDA Margin | -1.98% | 4.30% | 1.11% | 0.93% | 5.48% | 9.63% |
D&A For EBITDA | 0.29 | 0.32 | 0.31 | 0.35 | 0.34 | 0.34 |
EBIT | -1.25 | 2.02 | 0.25 | 0.12 | 2.75 | 5.78 |
EBIT Margin | -2.58% | 3.72% | 0.50% | 0.24% | 4.88% | 9.10% |
Effective Tax Rate | - | 60.81% | 58.21% | 134.00% | - | - |